PCM
TYRA icon

Pinz Capital Management’s Tyra Biosciences TYRA Stock Holding History

Pinz Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,700
Closed -$487K – 470
2021
Q3 		$487K Buy
+27,700
New +$529K 0.22% 71

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Pinz Capital Management's TYRA Position: Q4 2021 in Review

Pinz Capital Management sold out of Tyra Biosciences (TYRA) in Q4 2021, closing a stake of 27,700 shares — an estimated $487K sold.

Pinz Capital Management first reported a position in TYRA in Q3 2021 and held it in 1 quarter. The position peaked at $487K in Q3 2021. 45 funds tracked by Wall St. Rank hold TYRA as of Q4 2021.

  • Pinz Capital Management reported no remaining Tyra Biosciences position as of Q4 2021 after selling out during the quarter.
  • Pinz Capital Management sold 27,700 Tyra Biosciences shares in Q4 2021, an estimated $487K.
  • Pinz Capital Management first reported a position in Tyra Biosciences in Q3 2021 and held it in 1 quarter.
  • Pinz Capital Management's Tyra Biosciences position peaked at $487K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2021.

Based on Pinz Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.